MicroRNA in Glioblastoma: An Overview

Overview

Journal Int J Genomics

Publisher Wiley

Date 2017 Dec 14

PMID 29234674

Citations 78

Authors

Barbara Banelli

Alessandra Forlani

Giorgio Allemanni

Anna Morabito

Maria Pia Pistillo

Massimo Romani

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most aggressive brain tumor and, even with the current multimodal therapy, is an invariably lethal cancer with a life expectancy that depends on the tumor subtype but, even in the most favorable cases, rarely exceeds 2 years. Epigenetic factors play an important role in gliomagenesis, are strong predictors of outcome, and are important determinants for the resistance to radio- and chemotherapy. The latest addition to the epigenetic machinery is the noncoding RNA (ncRNA), that is, RNA molecules that are not translated into a protein and that exert their function by base pairing with other nucleic acids in a reversible and nonmutational mode. MicroRNAs (miRNA) are a class of ncRNA of about 22 bp that regulate gene expression by binding to complementary sequences in the mRNA and silence its translation into proteins. MicroRNAs reversibly regulate transcription through nonmutational mechanisms; accordingly, they can be considered as epigenetic effectors. In this review, we will discuss the role of miRNA in glioma focusing on their role in drug resistance and on their potential applications in the therapy of this tumor.

Citing Articles

Tight junction proteins in glial tumors development and progression.

Moskal J, Michalak S Front Cell Neurosci. 2025; 19:1541885.

PMID: 39963115 PMC: 11830821. DOI: 10.3389/fncel.2025.1541885.

Unveiling cell-type-specific microRNA networks through alternative polyadenylation in glioblastoma.

Cihan M, Schmauck G, Sprang M, Andrade-Navarro M BMC Biol. 2025; 23(1):15.

PMID: 39838429 PMC: 11752630. DOI: 10.1186/s12915-024-02104-8.

Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs.

Lanskikh D, Kuziakova O, Baklanov I, Penkova A, Doroshenko V, Buriak I Cells. 2025; 13(24.

PMID: 39768176 PMC: 11674823. DOI: 10.3390/cells13242085.

Epigenetic dysregulation in glioblastoma: potential pathways to precision medicine.

Prakash V, Gabrani R Neurogenetics. 2024; 26(1):5.

PMID: 39585441 DOI: 10.1007/s10048-024-00793-5.

The significance of miR-124 in the diagnosis and prognosis of glioma: A systematic review.

Ghasemi E, Mondanizadeh M, Almasi-Hashiani A, Mahboobi E PLoS One. 2024; 19(11):e0312250.

PMID: 39485747 PMC: 11530070. DOI: 10.1371/journal.pone.0312250.

References

Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J . MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res. 2011; 1389:9-18. DOI: 10.1016/j.brainres.2011.03.013. View

Parodi F, Carosio R, Ragusa M, Di Pietro C, Maugeri M, Barbagallo D . Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation. Biochim Biophys Acta. 2016; 1859(12):1502-1514. DOI: 10.1016/j.bbagrm.2016.10.006. View

Helin K, Dhanak D . Chromatin proteins and modifications as drug targets. Nature. 2013; 502(7472):480-8. DOI: 10.1038/nature12751. View

Kinnaird A, Zhao S, Wellen K, Michelakis E . Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016; 16(11):694-707. DOI: 10.1038/nrc.2016.82. View

Brandes A, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G . First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol. 2004; 22(9):1598-604. DOI: 10.1200/JCO.2004.11.019. View

Wuchty S, Arjona D, Li A, Kotliarov Y, Walling J, Ahn S . Prediction of Associations between microRNAs and Gene Expression in Glioma Biology. PLoS One. 2011; 6(2):e14681. PMC: 3040173. DOI: 10.1371/journal.pone.0014681. View

Li R, Chen L, Zhang H, Du W, Feng Y, Wang H . MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci Ther. 2013; 19(7):477-83. PMC: 6493424. DOI: 10.1111/cns.12089. View

Peng S, Dhruv H, Armstrong B, Salhia B, Legendre C, Kiefer J . Integrated genomic analysis of survival outliers in glioblastoma. Neuro Oncol. 2016; 19(6):833-844. PMC: 5464466. DOI: 10.1093/neuonc/now269. View

Zhao H, Shen J, Hodges T, Song R, Fuller G, Heimberger A . Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1):59. PMC: 5346242. DOI: 10.1186/s12943-017-0628-5. View

10.

Chen R, Cohen A, Colman H . Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Curr Treat Options Oncol. 2016; 17(8):42. DOI: 10.1007/s11864-016-0418-0. View

11.

Halle B, Marcusson E, Aaberg-Jessen C, Jensen S, Meyer M, Schulz M . Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. J Neurooncol. 2015; 126(1):47-55. DOI: 10.1007/s11060-015-1947-2. View

12.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

13.

Gillies J, Lorimer I . Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle. 2007; 6(16):2005-9. DOI: 10.4161/cc.6.16.4526. View

14.

Zhu S, Si M, Wu H, Mo Y . MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007; 282(19):14328-36. DOI: 10.1074/jbc.M611393200. View

15.

Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen M . Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 2010; 12(5):422-33. PMC: 2940621. DOI: 10.1093/neuonc/nop061. View

16.

Tili E, Michaille J, Wernicke D, Alder H, Costinean S, Volinia S . Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A. 2011; 108(12):4908-13. PMC: 3064319. DOI: 10.1073/pnas.1101795108. View

17.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

18.

Speranza M, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M . NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012; 3(7):723-34. PMC: 3443255. DOI: 10.18632/oncotarget.547. View

19.

Banelli B, Daga A, Forlani A, Allemanni G, Marubbi D, Pistillo M . Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget. 2017; 8(21):34896-34910. PMC: 5471020. DOI: 10.18632/oncotarget.16820. View

20.

Chen L, Zhang K, Shi Z, Zhang A, Jia Z, Wang G . A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncol Rep. 2014; 31(4):1573-80. DOI: 10.3892/or.2014.3012. View